Can-Fite BioPharma Ltd. (TLV:CANF)
Israel
· Delayed Price · Currency is ILS · Price in ILA 1.000
0.00 (0.00%)
At close: Dec 4, 2025
Can-Fite BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.56 | 0.67 | 0.74 | 0.81 | 0.85 | 0.76 | Upgrade
|
| Revenue Growth (YoY) | -16.04% | -9.29% | -8.27% | -5.04% | 11.80% | -62.45% | Upgrade
|
| Gross Profit | 0.56 | 0.67 | 0.74 | 0.81 | 0.85 | 0.76 | Upgrade
|
| Selling, General & Admin | 3.59 | 3.05 | 2.96 | 3.14 | 3.85 | 2.95 | Upgrade
|
| Research & Development | 5.91 | 5.76 | 5.98 | 7.76 | 9.85 | 11.95 | Upgrade
|
| Operating Expenses | 9.49 | 8.8 | 8.94 | 10.91 | 13.7 | 14.9 | Upgrade
|
| Operating Income | -8.93 | -8.13 | -8.2 | -10.1 | -12.84 | -14.14 | Upgrade
|
| Interest Expense | - | - | - | - | - | -0.36 | Upgrade
|
| Interest & Investment Income | 0.18 | 0.29 | 0.51 | 0.22 | 0.02 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0.06 | -0.05 | 0.06 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | Upgrade
|
| EBT Excluding Unusual Items | -8.79 | -7.87 | -7.65 | -9.94 | -12.78 | -14.45 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | -0.01 | 0.01 | -0.23 | 0.16 | 0.01 | Upgrade
|
| Pretax Income | -8.8 | -7.88 | -7.63 | -10.17 | -12.62 | -14.44 | Upgrade
|
| Earnings From Continuing Operations | -8.8 | -7.88 | -7.63 | -10.17 | -12.62 | -14.44 | Upgrade
|
| Net Income | -8.8 | -7.88 | -7.63 | -10.17 | -12.62 | -14.44 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 2.59 | 0.72 | Upgrade
|
| Net Income to Common | -8.8 | -7.88 | -7.63 | -10.17 | -15.21 | -15.16 | Upgrade
|
| Shares Outstanding (Basic) | 2,971 | 2,176 | 1,278 | 816 | 553 | 358 | Upgrade
|
| Shares Outstanding (Diluted) | 2,971 | 2,176 | 1,278 | 816 | 553 | 358 | Upgrade
|
| Shares Change (YoY) | 87.11% | 70.22% | 56.71% | 47.49% | 54.31% | 317.19% | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | -0.01 | -0.01 | -0.03 | -0.04 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.00 | -0.01 | -0.01 | -0.03 | -0.04 | Upgrade
|
| Free Cash Flow | -8.36 | -7.64 | -8.44 | -10.81 | -9.87 | -12.09 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.02 | -0.03 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -1595.36% | -1206.23% | -1102.96% | -1246.42% | -1505.51% | -1853.08% | Upgrade
|
| Profit Margin | -1571.25% | -1169.14% | -1027.46% | -1255.93% | -1782.53% | -1986.63% | Upgrade
|
| Free Cash Flow Margin | -1491.96% | -1133.83% | -1136.20% | -1334.57% | -1156.98% | -1584.40% | Upgrade
|
| EBITDA | -8.91 | -8.12 | -8.18 | -10.08 | -12.83 | -14.13 | Upgrade
|
| D&A For EBITDA | 0.03 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | Upgrade
|
| EBIT | -8.93 | -8.13 | -8.2 | -10.1 | -12.84 | -14.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.